Healthcare
Live Price
Offline$10.54
+8.10% today
1Y Change
+57.00%
Window
Jun 23, 2025 → Jun 9, 2026
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Personalis, Inc. (PSNL) is a Healthcare stock with a market cap of $510.00M and listed on NASDAQ. The stock last traded around $10.54 and up 57.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +33.6%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +33.6%, free cash flow -69.9% with operating margin -126.4% and ROIC -29.9%. Valuation sits in the middle of the pack at price/sales 7.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PSNL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PSNL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PSNL Max Drawdown
-55.20%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PSNL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$85.5M
+31.4% YoY
FY Net Income
-$65.2M
+42.4% YoY
Free Cash Flow
-$81.9M
+31.8% YoY
Revenue Growth
-100.0%
EPS Growth
+33.6%
Gross Margin
22.7%
Net Margin
-116.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 85M | 73M | 65M | 85M |
| Gross Profit | -54M | 27M | 18M | 13M | 32M |
| Operating Income | -88M | -68M | -110M | -116M | -65M |
| EBITDA | -71M | -70M | -97M | -105M | -59M |
| Net Income | -81M | -81M | -108M | -113M | -65M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 124M | 91M | 57M | 89M | 106M |
| Total Assets | 334M | 270M | 225M | 293M | 397M |
| Total Liabilities | 73M | 67M | 96M | 75M | 86M |
| Shareholder Equity | 261M | 203M | 129M | 218M | 310M |
| Total Debt | 32M | 44M | 48M | 49M | 58M |
| Net Debt | -92M | -47M | -9M | -40M | -47M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
71M
-0.8% YoY
Capital Expenditures
11M
+77.8% YoY
Free Cash Flow
82M
+31.8% YoY
Key ratios
Gross Margin
22.7%
Operating Margin
-126.4%
Net Margin
-116.7%
ROE
-39.1%
Debt / Equity
0.12x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.